Drug Index


Mechanism :

Rilonacept reduces inflammation by binding to IL-1ß (some binding of IL-1a and IL-1 receptor antagonist) and preventing interaction with cell surface receptors.

Indication :

  • For the treatment of cryopyrin-associated periodic syndromes
  • Familial cold autoinflammatory syndrome
  • Muckle-Wells syndrome in children 12 years and older.

Contraindications :

No contraindications.

Dosing :

≥12 years:
Initial 4.4 mg/kg SC (Maximum dose: 320 mg and not to exceed 160 mg per injection. If exceeding 160 mg, give as separate injections at 2 different sites). Maintenance: 2.2 mg/kg (Maximum dose: 160 mg) once weekly. Begin maintenance dose 1 week following loading dose.

Adverse Effect :

Antibody development, increased susceptibility to infections, injection site reactions, hypoesthesia.

Interaction :

Anti-TNF Agents: May enhance the adverse/toxic effect of Rilonacept.
Live Vaccines: Immunosuppressants may enhance the adverse/toxic effect of Live Vaccines.
Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity.

Hepatic Dose :

No dose adjustment recommended.
01/18/2024 19:56:10 Rilonacept
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0